Year-end Sale % OFF 
Abstract
Background and Aim: Liver Transplantation is an important treatment modality for patients with Hepatitis B related chronic liver disease. The risk of reinfection with Hepatitis B post-transplant is a grave concern. Current recommendations endorse use of both Hepatitis B immunoglobulin (HBIG) and antiviral drugs post-transplant. We report our center's experience with using only antiviral therapy post liver transplant. Methods: Data was collected on all patients undergoing liver transplantation for Hepatitis B related chronic liver disease at our center between FY 2006 and FY 2016. Results: During the 10 year study period a total of 234 patients underwent liver transplant for Hepatitis B related liver disease. No HBIG was given to the patients post transplant. They were only treated with antiviral therapy. We did not find any evidence of Hepatitis B reinfection in our patients during the 10-year study period. Conclusion: We report no incidence of Hepatitis B reinfection following liver transplantation in patients treated with only antiviral therapy. HBIG is an expensive medication and may not be required even in the immediate post-transplant period thus significantly reducing costs. The authors have none to declare.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
